Alzamend Neuro公司宣布,其针对重度抑郁症、创伤后应激障碍以及阿尔茨海默病的额外II期临床研究,预计将在2026年下半年度正式启动。这一进展标志着公司在神经疾病治疗领域的研发管线取得了重要推进。
Alzamend Neuro公司宣布,其针对重度抑郁症、创伤后应激障碍以及阿尔茨海默病的额外II期临床研究,预计将在2026年下半年度正式启动。这一进展标志着公司在神经疾病治疗领域的研发管线取得了重要推进。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.